Parallel Bio

Parallel Bio is a biotechnology company pioneering human-first drug discovery by creating scalable, immune-system-in-a-dish platforms. Its technology leverages human immune organoids combined with AI and automation to map biological landscapes and replicate human responses at population scale. By modeling diverse patient backgrounds and disease states, the platform allows researchers to evaluate drug candidates, immunotherapies, and vaccines, aiming to overcome the limitations and inaccuracies of traditional animal models in preclinical development. The system enables earlier, data-driven decisions that significantly reduce the time and cost associated with drug development while increasing the probability of clinical success.

The company's technology is designed to solve the high failure rates of new drugs in human trials by shifting from animal-based testing to human-centric modeling. Partners, including multiple Fortune 500 pharmaceutical companies, use the company’s Clinical Trial in a Dish application to test the efficacy and safety of drug candidates. This approach provides valuable insights into how therapies perform across varied genetic profiles, helping to identify promising targets and safer drug candidates before human clinical trials begin. Founded in 2021, Parallel Bio continues to expand its biobank and computational tools to transform the drug discovery process and support the advancement of personalized medicine.